Bank predicts double blockbuster status for Novo obesity drug next year
Novo Nordisk's weight loss drug Wegovy could be heading for double blockbuster status as soon as next year, according to an analysis by Danske Bank, which has almost doubled its previous expectations for the medicine.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
The obesity drug Wegovy, developed by Novo Nordisk, could reach double blockbuster status as soon as next year, estimates an analysis from Danske Bank, reports media PLX.AI.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk hopes to stabilize Wegovy supply in early 2022
For subscribers
